# AstraZeneca and Roche Diagnostics Asia Pacific announce a three-year Memorandum of Understanding.

*biotech · news · 2026-05-18 · The Tribune*

## Key points

- AstraZeneca and Roche Diagnostics signed a first-in-region three-year MoU to advance digital pathology in Asia.
- AI-powered workflows can reclassify 24% of HER2-negative breast cancer cases as HER2-low, expanding therapy access.
- Only 17% of clinicians in Asia are very aware of advanced pathology technologies, revealing a major adoption gap.
- Roche received FDA Breakthrough Device designation for the first AI-powered TROP2 companion diagnostic for lung cancer.
- Educational initiatives will target nine Asia markets to accelerate AI-assisted pathology adoption in cancer care.

**Companies:** AstraZeneca, Roche Diagnostics
**Countries:** Singapore, Taiwan, Korea, Thailand, Malaysia, India, Indonesia, Vietnam, Philippines

[Read the full story on The Tribune](https://www.tribuneindia.com/news/business/astrazeneca-collaborates-with-roche-diagnostics-asia-pacific-to-help-accelerate-sustainable-ecosystem-for-advanced-pathology-in-breast-and-lung-cancer/)

---

Canonical: https://newsio.io/n/edcc8e1d-6a6c-45ab-8364-925797d3e860/astrazeneca-and-roche-diagnostics-asia-pacific-announce-a-three-year-memorandum
Summarized by Newsio from The Tribune. https://newsio.io/how-it-works